Purdue, Actavis Settle OxyContin Patent Battle
Purdue Pharma LP and Actavis Inc. announced Friday that they've agreed to end a New York patent infringement suit seeking to block Actavis' generic version of abuse-deterrent formulations of Purdue's multibillion-dollar...To view the full article, register now.
Already a subscriber? Click here to view full article